(4502) – Globe Newswire
-
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
-
Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations
-
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
-
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
-
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
-
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
-
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
-
Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma
-
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
-
CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally
-
CENTOGENE Extends Partnership With Takeda
-
Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel
-
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
Back to 4502 Stock Lookup
